Tag: Broad

Categories
Health

Sacklers Threaten to Pull Out of Opioid Settlement With out Broad Authorized Immunity

Sacklers Threaten to Pull Out of Opioid Settlement Without Broad Legal Immunity

At least 2,700 lawsuits and hundreds of thousands of lawsuits have been registered against Purdue, beginning in 2014 when the opioid epidemic peaked. Plaintiffs span a broad spectrum including 48 states, local governments, tribes, hospitals, individuals and caregivers of infants born with symptoms of withdrawal from opioids, all of whom are devastated and financially exhausted from opioids.

In the last few years, more and more cases, individual sackers have been named themselves.

Nearly two years ago, Purdue filed for bankruptcy restructuring that automatically suspended those lawsuits. However, the Sacklers themselves did not file for bankruptcy, despite insisting that they too benefit from their company’s expected indemnities.

The issue of releases for the Sacklers and other third parties is at the center of opposition to the bankruptcy scheme that is now being pursued by nine states, including Maryland, Washington and Connecticut. The District of Columbia, the Federal Department of Justice and the U.S. Trustee, a Department of Justice program that monitors bankruptcy cases, as well as several Canadian local governments and First Nations have joined in the opposition.

Under applicable law of the Second Circuit Court of Appeals, where the Judge Drain Court is located, the judge may grant exemptions to the Sacklers and other third parties who have not filed for bankruptcy. But, by and large, the issue is unresolved.

Other federal districts prohibit it. The issue has been taken up by members of Congress and could well lead to an appeal by the opponents if Judge Drain approves the plan. The pounding questions of contradicting attorneys so far should not only raise questions about the plan, but lay a foundation for such appeals.

Alain Delaquérière contributed to the research.

Categories
Health

W.H.O. Testing three Medicine in Broad Seek for Covid Remedies

W.H.O. Testing 3 Drugs in Broad Search for Covid Treatments

The World Health Organization is testing three more drugs as part of a huge global study to find effective treatments for Covid-19, the agency said on Wednesday.

The study, which will involve researchers in more than 600 hospitals in 52 countries, will evaluate whether the drugs already approved for other uses – one for malaria, one for cancer and one for autoimmune diseases – can reduce the risk of death for patients with Covid to be hospitalized.

Dr. Tedros Adhanom Ghebreyesus, WHO director general, said Wednesday he hoped “one or more of the drugs” would prove effective in treating the virus.

Although there are already some treatments out there for people with Covid-19, including steroids and monoclonal antibodies, Dr. Tedros: “We need more for patients at all ends of the clinical spectrum.”

The first phase of the WHO’s trials of new drugs, which it called Solidarity, yielded disappointing results. The researchers found that four different drugs, including hydroxychloroquine and the antiviral drug remdesivir, had little or no benefit for hospitalized Covid patients.

The three drugs in the new study, named Solidarity Plus, were selected by an independent panel of experts and are donated by their manufacturers Ipca, Novartis and Johnson & Johnson. The drugs are artesunate, an antimalarial drug that may have anti-inflammatory effects; Imatinib, a cancer drug that could reverse damage to the lungs; and infliximab, an autoimmune disease drug that may help curb an overly aggressive immune response to the virus.

Categories
World News

Home committee passes broad tech antitrust reforms

House committee passes broad tech antitrust reforms

A House Committee passed a series of comprehensive cartel reforms on Thursday after around 23 hours of debate.

While the advancement of the six technology-oriented bills that will be debated by the House Judiciary Committee starting Wednesday is a victory for the bipartisan members who brought them in, the impact opened rifts within the parties that could ultimately affect the chances of the bills To become law.

Several lawmakers made it clear that they believed the rollout-to-markup process arrived prematurely in less than two weeks despite a lengthy investigation before the bills. Some said they were hoping for more changes before the legislation reaches parliament.

Nonetheless, the final stage of the debate offered some signs of optimism to those hoping to move the bills forward. Fresh from a break after the Fifth Act was passed after 5 a.m. on Thursday, lawmakers returned to the committee room at around 11:30 a.m. to discuss the Ending Platform Monopoles Act

The bill – sponsored by Antitrust Subcommittee Vice Chair Pramila Jayapal, D-Wash., And co-sponsored by Rep. Lance Gooden, R-Texas – would prevent dominant platforms from owning businesses that present conflicts of interest, such as through incentives preferring their own products to their service-dependent competitors.

The bill was one of the most aggressive in the package, including updates to merger filing fees for dominant platforms, a shift in the burden of proof for acquisitions, and a provision for attorneys general to have a say in the jurisdiction of their antitrust proceedings. It could essentially force the dissolution of companies like Amazon and Apple, both of which sell products or services on their own marketplaces that also serve third parties. Both stocks closed slightly lower for the day.

Despite the huge impact of the bill, it wasn’t the most controversial. The legislature has argued about the mandate for data portability under the Access Act for much longer than when it assessed potential security problems, for example.

Jayapal’s bill also sparked a lively debate. In the end, the vote was similar to the others (it was passed at 21:20, supported by Democrats and MPs Ken Buck, R-Colo. And Matt Gaetz, R-Fla., And against the Republicans supported by Rep. Greg. Stanton, D-Ariz., And the California Democrats Lou Correa, Zoe Lofgren and Eric Swalwell). Throughout the discussion, however, it was clear that many in the group broadly agreed with the principles of the bill, even though they felt it could use some fine-tuning.

“I’m telling you, I’m not 100% there to destroy big tech, but I’m close,” said Rep. Dan Bishop, RN.C. “And this is the calculation that, if done right, would be the vehicle to put that on the table.”

Although an amendment he proposed failed, Antitrust Subcommittee Chairman David Cicilline, DR.I. and Jayapal expressed a willingness to work with Bishop to possibly include a reference to his idea in the bill. Bishop was essentially trying to bring antitrust cases to court by removing a regulatory move. Cicilline had called it “the most interesting change in markup,” although he didn’t endorse it, and Justice Committee chairman Jim Jordan, R-Ohio called it “the change.”

In a post-markup interview Thursday, Buck, the senior member of the antitrust subcommittee that supported the legislation, told CNBC he expected more work to be done before the bills move forward.

“I don’t think the bills will be down for a couple of months because of the August break, so I think the opportunity to work together is certainly there,” he said.

It is clear that even after such a long debate, there is still a lot of work to be done on the drafters of the bill. After the service was adjourned, bipartisan members of the California delegation issued a joint statement in committee urging further revision of the bill despite its approval by the committee. They also said committee members did not have enough time to properly review the bills before serving.

“The legislative text as debated is far from ready for Floor,” wrote Correa, Swalwell, Lofgren and Reps. Darrell Issa, R-Calif., And Tom McClintock, R-Calif. “We urge sponsors of the bills to take the time necessary to commit to a comprehensive approach and to work with their bipartisan counterparts on this committee to address the concerns raised during the markup in order to further develop these bills.”

Responding to criticism from his colleagues who felt they did not have enough time to review the bills, Buck said that “it is a common objection” but that “the ideas in the bill have been summarized in reports written last October “.

Subscribe to CNBC on YouTube.

WATCH: How US Antitrust Law Works and What It Means for Big Tech

Categories
Politics

Broad Coalition of Democrats Presses Biden to Broaden Medicare

Broad Coalition of Democrats Presses Biden to Expand Medicare

WASHINGTON – A broad coalition of Democrats from across the ideological spectrum plans on Thursday to begin what it promises to be a loud and sustained campaign to pressure President Biden to add a major Medicare addition to his infrastructure package.

More than 150 House Democrats – including Representative Pramila Jayapal of Washington, chairman of the progressive wing of the House, and Representative Jared Golden of Maine, one of the chamber’s most centrist Democrats – have teamed up in what is far from certain to draw Republican opposition but contains suggestions that are popular with a broad segment of the electorate.

Disappointed that Mr Biden has not yet responded to an election promise to expand Medicare benefits, members of the group, which together represent nearly 70 percent of House Democrats, have signed a letter starting their print campaign. The organizers say it will contain opinion pieces and press events. Representatives Conor Lamb from Pennsylvania and Joe Neguse from Colorado are also leading the push.

“It is really unusual for a health proposition to reach this intensity,” Ms. Jayapal said in an interview.

At the heart of the plan is to call for the Medicare Eligibility Age to be lowered from 65 to 60 and to enroll approximately 23 million Americans on the federal senior health program, which will cost $ 200 billion over 10 years. Lawmakers are also pushing for Medicare benefits to be extended to include teeth, eyesight and hearing, which would cost approximately $ 350 billion over 10 years.

Legislators say the third element of their package more than offsets the cost: Medicare’s power to negotiate drug prices. Ms. Jayapal said change – one that Democrats have been unsuccessful in promoting for years – could generate as much as $ 650 billion in a decade, although the Congressional budget bureau has estimated the savings at about $ 450 billion over that period.

Mr Golden, who has historically opposed some large-ticket spending, including the nearly $ 1.9 trillion stimulus bill, said the Department of Veterans Affairs, which has the power to negotiate drug prices for veterans, is paying far less for prescription drugs than the rest of the government.

The Government Accountability Office found that the prescription drug division paid an average of 54 percent less than Medicare in 2017.

Lawmakers have made Zoom calls with White House officials over the proposal, which they hope Mr Biden will include in a large spending package that can lead the Senate through accelerated budget reconciliation this year.

It is not clear whether Mr Biden and other Democrats in Congress will accept the move, as Democratic leaders have focused on competing efforts to achieve a permanent increase in health subsidies under the Affordable Care Act in the Boom Act. There is widespread support for this proposal, including from hospitals who want to get the higher private insurance rates and insurers who want more people to buy their products. Any attempt to expand Medicare is likely to encounter opposition from the same groups.

Updated

May 26, 2021, 9:17 p.m. ET

However, Ms. Jayapal argued that the two health care proposals were compatible. She said negotiating lower drug prices could generate enough money to pay for the changes to the Affordable Care Act as well. If not, “there are many sources of income that are possible and necessary,” she said.

The Medicare proposals have proven popular with so-called Front Democrats – those who represent conservative districts. More than a dozen have joined the effort, underscoring its bipartisan appeal.

After meeting with White House officials on the matter, Neguse argued that Democrats could go further and lower the Medicare Eligibility Age to 55 to cover more than 40 million additional people.

“Many seniors in our nation cannot treat their illnesses because Medicare benefits are not as comprehensive as they should be,” he said.

Democrats say that at least 75 percent of Medicare beneficiaries who require a hearing aid do not have a hearing aid, and much of the country has low rates for dental visits or eye exams.

Mr. Golden said when speaking to voters he had heard repeatedly that the change would help the residents of his district.

“How crazy is it that we have been paying into Medicare all our professional lives, and at the time when your dental care is likely to be the most important, Medicare doesn’t even cover it?” he said. “I know seniors get frustrated with this.”

Nearly 20 Senators, led by Senator Bernie Sanders, the independent Vermonter, have joined forces on a similar call for White House action on the matter.